570 related articles for article (PubMed ID: 21426769)
41. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
Ødegaard E; Davidson B; Elgaaen BV; Fagerhol MK; Engh V; Onsrud M; Staff AC
Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
[TBL] [Abstract][Full Text] [Related]
42. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
43. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
[TBL] [Abstract][Full Text] [Related]
44. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
[TBL] [Abstract][Full Text] [Related]
45. [Clinical analysis of benign pelvic mass with high serum levels of CA(125)].
Zhang X; Wu LY; Li XJ; Li HJ; Zhang R; Liu LY
Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):178-82. PubMed ID: 15840313
[TBL] [Abstract][Full Text] [Related]
46. Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization.
Morohoshi K; Patel N; Ohbayashi M; Chong V; Grossniklaus HE; Bird AC; Ono SJ
Exp Mol Pathol; 2012 Feb; 92(1):64-73. PubMed ID: 22001380
[TBL] [Abstract][Full Text] [Related]
47. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
48. Anti-ovarian antibodies in sera of patients with ovarian tumors.
Szubert S; Michalak S; Szpurek D; Moszynski R; Krygowska-Zielinska J; Sajdak S
Immunol Lett; 2012 Dec; 148(2):133-7. PubMed ID: 23026238
[TBL] [Abstract][Full Text] [Related]
49. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
50. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
52. The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome.
Hoxha A; Ruffatti A; Pittoni M; Bontadi A; Tonello M; Salvan E; Plebani M; Punzi L
Clin Chim Acta; 2012 May; 413(9-10):911-3. PubMed ID: 22349599
[TBL] [Abstract][Full Text] [Related]
53. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
54. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
[TBL] [Abstract][Full Text] [Related]
55. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
[TBL] [Abstract][Full Text] [Related]
56. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer.
Longoria TC; Ueland FR; Zhang Z; Chan DW; Smith A; Fung ET; Munroe DG; Bristow RE
Am J Obstet Gynecol; 2014 Jan; 210(1):78.e1-9. PubMed ID: 24055582
[TBL] [Abstract][Full Text] [Related]
57. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
58. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
[TBL] [Abstract][Full Text] [Related]
59. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
60. Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer.
Chen M; Lin X; Zhang L; Yu L; Wu Q; Zhang S; Xue F; Huang Y
Int J Med Sci; 2020; 17(17):2744-2750. PubMed ID: 33162802
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
